An Introduction to Breast Cancer
New perspectives in cancer therapy have led to rapid progress in breast cancer research. Some of the most exciting recent developments include ongoing studies aiming to enhance current breast cancer screening options, as well as approval of several poly-ADP ribose polymerase (PARP) inhibitors. Other areas of active research include histone deacetylase (HDAC) inhibitors and chimeric antigen receptor (CAR) T-cell therapies.
Browse our selection of video highlights and short articles from the conference hub, which provide insights into the latest updates from major conferences, and a collection of peer-reviewed articles from the journal portfolio. These are complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Our supporting partners do not constitute an endorsement of the content on this page.
Breast Cancer Content
Trastuzumab Deruxtecan for the Treatment of HER2-positive Breast Cancer
touchREVIEWS in Oncology & Haematology. 2023;19(1):6–10 DOI: https://doi.org/10.17925/OHR.2023.19.1.6
Trastuzumab deruxtecan (T-DXd) is a highly effective drug for the treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced recurrent breast cancer. It was approved by the US Food and Drug Admninistration even though it had only been through a phase II study. It has attracted a great deal of attention among oncologists, and many clinical trials have been conducted. This article reviews reports of […]
Tailoring the Treatment of Early-stage HER2-positive Breast Cancer: One Size Does Not Fit All
touchREVIEWS in Oncology & Haematology. 2023;19(1):11-16 DOI: https://doi.org/10.17925/OHR.2023.19.1.11
Human epidermal growth factor receptor-2 (HER2)-positive breast cancer accounts for 15% of all breast cancers.1 This breast cancer subtype was historically associated with poor outcomes; however, the development of HER2-directed therapies has dramatically improved outcomes for patients with both early and advanced HER2+ disease.2 Currently, there are several types of HER2-targeted agents approved for the […]
Sara Hurvitz, SABCS 2022: Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2+ metastatic breast cancer: DESTINY-Breast03
Trastuzumab deruxtecan (T-DXd) is approved in the United States and European Union for use in patients with HER2+ unresectable/metastatic breast cancer. Approval was based on the randomized, multicenter, open-label, phase III DESTINY-Breast03 (NCT03529110) trial. In this interview we discuss with Dr Sara Hurvitz (David Geffen School of Medicine, UCLA Los Angeles, CA, USA) updated data […]
Erika Hamilton, SABCS 2022: Trastuzumab deruxtecan and pertuzumab in HER2+ metastatic breast cancer
Preclinical findings have suggested that when used in combination with anticancer treatments, trastuzumab deruxtecan (T-Dxd) could improve treatment efficacy in HER2+ metastatic breast cancer (mBC). In this interview we discuss with Dr Erika Hamilton (Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN) preliminary data from the dose expansion phase of the DESTINY-Breast07 (DB-07) (NCT04538742) trial. […]
Sudeep Gupta, SABCS 2022: Addition of platinum to neoadjuvant chemotherapy in patients with triple-negative breast cancer: A phase III randomized controlled trial
The impact of adding platinum on long-term outcomes in triple-negative breast cancer (TNBC) has not been definitively established. The controlled, single-centre, phase III study conducted by Tata Memorial Hospital in Mumbai, India evaluated the efficacy and toxicity of adding platinum to standard neoadjuvant chemotherapy in patients with triple-negative breast cancer. In this touchONCOLOGY interview, we speak […]
Mafalda Oliveira, SABCS 2022: Camizestrant vs fulvestrant in women with advanced ER+ HER2- breast cancer: The SERENA-2 trial
The SERENA-2 trial (NCT04214288) is a randomised, multicentre phase II trial evaluating camizestrant at several dose levels compared to fulvestrant in advanced ER-positive, HER2-negative breast cancer. In this touchONCOLOGY interview, we speak with Dr Mafalda Oliveira (Vall d’Hebron University Hospital Barcelona, Spain) who gives an overview of the SERENA-2 trial and the advantages for the use […]
Claudine Isaacs, SABCS 2022: Cemiplimab plus REGN3767 in HER2-negative breast cancer: The I-SPY2 trial
The I-SPY2 trial (NCT01042379) is a multicentre, phase 2 trial where patients with HER2-negative breast cancer were randomized to receive neoadjuvant cemiplimab plus REGN3767 and paclitaxel or weekly paclitaxel for 12 cycles. In this touchONCOLOGY interview, we speak with Prof. Claudine Isaacs (Georgetown University, Washington, DC, USA) who gives an overview of the I-SPY2 study […]
APT trial: adjuvant paclitaxel and trastuzumab trial for node-negative HER2+ breast cancer – Sara Tolaney, SABCS 2022
The APT trial investigates adjuvant paclitaxel and trastuzumab in patients with node negative HER2+ breast cancer. Dr Sara Tolaney (Harvard Medical School, Boston, MA, USA) discusses the end-of-study, 10-year survival outcome results and explore what the study has demonstrated in terms of the role of the HER2DX genomic assay in predicting long-term outcomes (NCT00542451). The […]
Judy Boughey, SABCS 2022: Breast conservation therapy in patients with multiple ipsilateral breast cancer – The ACOSOG (Alliance) Z11102 trial
The ACOSOG (Alliance) Z11102 (NCT01556243) phase II single arm prospective trial evaluated how well breast-conserving surgery and radiation therapy worked in treating patients with multiple ipsilateral breast cancer. In this touchONCOLOGY interview, we speak with Prof. Judy Boughey (Mayo Clinic, Rochester, MN, USA) who gives an overview on multiple ipsilateral breast cancer and also discusses […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!